Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 20:8:640.
doi: 10.3389/fonc.2018.00640. eCollection 2018.

Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma

Affiliations

Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma

Chen Wang et al. Front Oncol. .

Abstract

Purpose: Radioiodine (131I) thyroid remnant ablation is an important treatment of differentiated thyroid carcinoma (DTC) and various factors affecting its efficacy have been reported but not well defined. The aim of our study was to evaluate the efficacy and the affecting factors of 131I ablation after total or near-total thyroidectomy in a relative large DTC cohort. Methods: 261 DTC patients with negative thyroglobulin antibody received 100-200 mCi 131I for thyroid remnant ablation after total or near-total thyroidectomy between January 2012 and October 2015 in our hospital. The efficacy and affecting factors of 131I ablation therapy were retrospectively investigated. Results: The success rate of the first 131I thyroid remnant ablation was 65.90%. Univariate analysis demonstrated that larger tumor size, higher level of pre-ablation stimulated thyroglobulin (sTg), intermediate to high risk stratification for recurrence, and lymph node and distant metastases were associated with a lower success rate of the first 131I ablation (all p < 0.05). Multivariate logistic regression analysis showed that tumor size, pre-ablation sTg, and lymph node and distant metastases were independent factors affecting the efficacy of the first 131I ablation. Areas under receiver operating characteristic curves for sTg, sTg/TSH ratio, and tumor size to predict unsuccessful ablation were 0.831, 0.824, and 0.648, respectively. The threshold values were 4.595 ng/ml, 0.046 mg/IU, and 1.350 cm, respectively. The sensitivities were 95.51, 96.63, and 73.03% and the specificities were 64.54, 61.63, and 49.41%, respectively. The excellent response (ER) ratio of the successful group was significantly higher than that of the unsuccessful group. Conclusions: The efficacy of the first 131I thyroid remnant ablation after surgical treatment of DTC is well demonstrated, and tumor size, pre-ablation sTg, lymph node, and distant metastases are independent factors affecting its efficacy.

Keywords: affecting factors; differentiated thyroid carcinoma; iodine-131; remnant ablation; thyroglobulin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The receiver operating characteristic (ROC) curves for sTg, sTg/TSH ratio and tumor size before 131I ablation to predict unsuccessful ablation. ROC curve analysis was constructed to determine the best cut-off values of sTg, sTg/TSH ratio, and tumor diameter (as indicated) before 131I ablation for predicting the unsuccessful ablation and to assess the predict values of the affecting factors.

References

    1. Kim TY, Kim WG, Kim WB, Shong YK. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab. (2014) 29:217–25. 10.3803/EnM.2014.29.3.217 - DOI - PMC - PubMed
    1. Yang X, Liang J, Li TJ, Yang K, Liang DQ, Yu Z, et al. . Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer. Chin Med J. (2015) 128:1058–64. 10.4103/0366-6999.155086 - DOI - PMC - PubMed
    1. Lee SJ, Jung SL, Kim BS, Ahn KJ, Choi HS, Lim DJ, et al. . Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma. Korean J Radiol. (2014) 15:817–26. 10.3348/kjr.2014.15.6.817 - DOI - PMC - PubMed
    1. Shaha A. Prognostic factors in papillary thyroid carcinoma and implications of large nodal metastasis. Surgery (2004) 135:237–9. 10.1016/j.surg.2003.08.023 - DOI - PubMed
    1. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. (2001) 86:1447–63. 10.1210/jcem.86.4.7407 - DOI - PubMed

LinkOut - more resources